Table 3

Immune response following vaccination stratified according to age irrespective of number of doses
All patients (number = 291) RA on MTX (number = 50) RA on anti-TNF monotherapy (number = 38) RA on anti-TNF + MTX (number = 53) RA on abatacept (number = 5) RA on rituximab (number = 10) RA on tocilizumab (number = 2) SpA on anti-TNF monotherapy (number = 41) SpA on anti-TNF + MTX (number = 51) SpA on NSAIDs/ analgesics controls (umber = 41)
60 years
Patients (number) 149 36 27 35 2 7 1 10 16 15
GMT prevaccination mean (95% CI) 8.1 (7.2 to 9.2) 8.6 (6.5 to 11.3) 9.5 (6.5 to 13.8) 6.3 (5.3 to 7.6) ---- 6.1 (3.8 to 9.9) --- 8.7 (5.2 to 14.5) 12 (8 to 17.6) 7.2 (5.3 to 10)
GMT postvaccination mean (95% CI) 30 (24.3 to 37) 26.2 (17.2 to 39.9) 42.1 (22.7 to 78.1) 24.9 (16.8 to 36.8) ---- 12.2 (5.5-27.2) ---- 92 (46 to 184) 19 (11.7 to 31.4) 42 (18.6 to 95)
Geometric mean fold increase (95% CI) 3.7 (3 to 4.6) 3.1 (2 to 4.8) 4.4 (2.5 to 7.8) 3.9 (2.5 to 6.2) ---- 2 (1.1-3.8) ---- 10.6 (6.2 to 18) 1.6 (0 to 9-3) 5.8 (2.4 to 14.1)
Patients with prevaccination titer ≥40 (n;%) 9(6%) 5 (14%) 2 (7%) 1 (3%) 0 0 0 0 1 (6%) 0%
Patients with postvaccination titer ≥40 (seroprotection) 72(48%) 15 (42%) 15 (56%) 14 (40%) 0 2 (29%) 1 (100%) 8 (80%) 7 (44%) 10 (67%)
Patients with positive immune response (seroconvers.) 60( 40%) 12 (33%) 13 (48%) 13 (37%) 0 1 (14%) 1 (100%) 8 (80%) 4 (25%) 9 (60%)
% immunized with seasonal influenza vaccine (2009/2010) 51% 64% 56% 43% 50% 43% 100% 50% 56% 27%
18-60 years
Patients (number) 142 14 11 18 3 3 1 31 35 26
GMT prevaccination mean (95% CI) 10 (8.7 to 11.4) 8.6 (5.5 to 13.5) 10 (6 to 16.7) 7.9 (5.7 to 11.1) 40 (7.1 to 224) 12.6 (1.7 to 92) --- 9.4 (7.1 to 12.4) 9.8 (7.5 to 13) 10.8 (7.5 to 16)
GMT postvaccination mean (95% CI) 58 (46.1 to 73) 98 (40 to 235) 66 (19 to 227) 39 (17.7 to 84) 64 (4.6 to 881) 8 (1.1 to 58) --- 72 (47 to 110) 51 (33 to 78) 60 (35.7 to 100)
Geometric mean fold increase (95% CI) 5.8 (4.5 to 7.6) 11.3 (4.4 to 29) 6.6 (1.9 to 23.5) 4.8 (2 to 11.6) 1.6 (0.2 to 12) 0.6 (0.1 to 4.6) --- 7.7 (4.5 to 13) 5.2 (3 to 8.8) 5.5 (3.2 to 9.5)
Patients with prevaccination titer ≥40 (n;%) 16 (11%) 1 (7%) 1 (9%) 0 2(67%) 0 1 (100%) 3 (10%) 3( 9%) 5 (19%)
Patients with postvaccination titer ≥40 (seroprotection) 95 (67%) 10 (71%) 7 (64%) 10 (56%) 2 (67%) 0 1 (100%) 23 (74%) 25 (71%) 17 (65%)
Patients with positive immune response (seroconvers.) 86 (61%) 9 (64%) 7 (64%) 10 (56%) 1 (33%) 0 1 (100%) 23 (74%) 20 (57%) 15 (58%)
% immunized with seasonal influenza vaccine (2009/2010) 20% 14% 9% 39% 33% 0 100% 13% 14% 27%

Positive immune response, that is seroconversion, was defined as prevaccination titers <10 and postvaccination HI titers ≥40 or a ≥4-fold increase in HI titers. CI, confidence interval; GMT, geometricial mean antibody titer; HI, hemagglutination inhibition; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; SpA, spondylarthropathy.

Kapetanovic et al.

Kapetanovic et al. Arthritis Research & Therapy 2014 16:R2   doi:10.1186/ar4427

Open Data